TCT Late-Breaker: Point-Of-Care Genetic Test Guides Antiplatelet Therapy
This article was originally published in The Gray Sheet
Executive Summary
Data presented at TCT may support rapid, point-of-care genetic testing in tailoring antiplatelet therapy, but clinicians are still not convinced.
You may also be interested in...
American Heart Association In Brief
Study results on ICD programming, biventricular pacing and more from the 2012 AHA Scientific Sessions in Los Angeles.
GIFT Study: Genetic Testing Viable For Personalizing Antiplatelet Therapy
A recent study supports a role for genetic testing as a means of personalizing antiplatelet therapy following stent placement and builds the case that newer drugs, such as Eli Lilly/Daiichi Sankyo's Effient (prasugrel), are more appropriate options for those who have poor response to standard Plavix (clopidogrel) treatment.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”